Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

person Kim Anna Reiss University of Pennsylvania, Philadelphia, PA info_outline Kim Anna Reiss, Sung Chul Hong, Anup Kasi, Eileen Mary O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriela Chiorean, Philip Agop Philip, Peter J. O'Dwyer

Authors person Kim Anna Reiss University of Pennsylvania, Philadelphia, PA info_outline Kim Anna Reiss, Sung Chul Hong, Anup Kasi, Eileen Mary O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriela Chiorean, Philip Agop Philip, Peter J. O'Dwyer Organizations University of Pennsylvania, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA, University of Kansas Cancer Center, Westwood, KS, Memorial Sloan Kettering Cancer Center, New York, NY, Winship Cancer Center of Emory University, Atlanta, GA, Cleveland Clinic Martin Health Florida, Stuart, FL, City of Hope National Medical Center, Duarte, CA, Sheba MC, Ramat Gan, Israel, Johns Hopkins University School of Medicine, Washington, DC, Mass General Cancer Center, Boston, MA, Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, University of Washington, Seattle, WA, Hoag Family Cancer Institute, Newport Beach, CA, University of Pennsylvania Department of Medicine, Philadelphia, PA Abstract Disclosures Research Funding U.S. National Institutes of Health U.S. National Institutes of Health, PANCAN Background: A meaningful subset of PDAC is characterized by a homologous recombination deficiency (HRD). The most well-defined patients within this group are those with pathogenic variants in BRCA1, BRCA2 and PALB2 . In the metastatic setting, PARP inhibitor maintenance provides a progression-free survival benefit after a period of platinum based chemotherapy 1,2 , but the role of PARP inhibitors in the curative intent setting is undefined. The OlympiA study established one year of olaparib as the standard of care for patients with BRCA -related, early stage breast cancer who completed all other curative-intent treatment 3 . Therefore, we have designed a randomized, phase II double-blind study of one year of olaparib vs placebo in patients with pancreatic cancer and a germline or somatic variant in BRCA or PALB2 who have completed all curative intent therapy. Methods: We have enrolled and treated 29 of 152 planned patients on study NCT 04858334/EA2192. Eligibility criteria include: a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2 as determined by local laboratory (central review required); completion of curative-intent resection and ≥ three months of multi-agent chemotherapy; no evidence of recurrent disease. At enrollment, patients must be within 12 weeks of their last anti-cancer intervention. Patients are randomized 2:1 to receive oral olaparib 300 mg twice daily or placebo for 12 28-day cycles. The primary endpoint is relapse-free survival. Overall survival is a secondary endpoint. Tumor tissue, fecal material (for microbiome analysis) and serial ctDNA samples are being collected. 1) Golan T, Locker GY, Kindler HL: Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. N Engl J Med 381:1492-1493, 2019. 2) Reiss KA, Mick R, O'Hara MH, et al: Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 39:2497-2505, 2021. 3) Tutt ANJ, Garber JE, Geyer CE, Jr.: Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply. N Engl J Med 385:1440, 2021. Clinical trial information: NCT04858334.

Clinical